Main
Sir,
Drs Mason, Johnson and Rudd suggest that criticism of the guidance issued by the National Institute for Clinical Excellence (NICE) regarding the use of irinotecan and oxaliplatin in the treatment of patients with advanced colorectal cancer may have implications for the FOCUS trial (Cunningham et al, 2002; Mason et al, 2002; NICE, 2002; Saunders and Valle, 2002). However, the reason for criticism of the NICE guidance is due to the overwhelming evidence that access to the three drugs 5-fluorouracil, irinotecan and oxaliplatin is the optimal therapeutic approach to metastatic colorectal cancer. Subsequent to this guidance entry into the revised FOCUS protocol is the only way that patients in the UK can access all these agents. Therefore, patients not participating in the FOCUS trial will receive suboptimal therapy. Although the median survival for FOCUS of 16 months is encouraging, and certainly a major step forward over CRO6 with a median survival of approximately 10 months (Maughan et al, 2002), it remains significantly less than that for patients treated with all three agents in randomised trials such as N9741 (Goldberg et al, 2002) and the Tournigand trial (Tournigand et al, 2001) with median survivals of 18.6 months (data presented at the American Society of Clinical Oncology, Orlando, 2002) and approximately 21 months (data presented at the American Society of Clinical Oncology, San Francisco, 2001).
While recognising there may be merit in fine-tuning the sequence of use of these three agents (combinations vs monotherapy), the crucial point is that all patients should have access to these three drugs.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cunningham D, Begent R, Bessell E, Bridgewater J, Carmichael J, Cassidy J, Coxon F, Daniel F, Falk S, Gildersleve J, Glynne-Jones R, Hawkins R, Hickish T, Hill M, Hochauser D, Iveson T, James R, Levine E, Mainwaring P, Maraveyas A, O'Byrne K, Radstone D, Saunders M, Smith D, Steward W, Twelves C, Valle J, Wasan H (2002) Cancer patients' treatment limited. The Daily Telegraph. London
Goldberg RM, Morton R, Sargent D, Fuchs C, Ramanathan R, Williamson S, Findlay B (2002) N9741: oxaliplatin (oxal) or CPT-11+5-fluorouracil (5FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI intergroup study. Proc Am Soc Clin Oncol 21: 128a (abstract 511)
MasonQ2 M, Johnson P, Rudd R (2002) Br J Cancer
Maughan T, James R, Kerr D, Ledermann J, McArdle C, Seymour M, Cohen D, Hopwood P, Johnston C, Stephens R, Party ftBMCCW (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359: 1555–1563
NICE (2002) Guidance on the use of irinotecan, oxaliplatin and Q3raltitrexed for the treatment of advanced colorectal cancer. Technology Appraisal Guidance No. 33. National Institute for Clinical Excellence
Saunders M, Valle J (2002) Why hasn't the National Institute been ‘NICE’ to patients with colorectal cancer. Br J Cancer 86: 1667–1669
Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, Ganem G, Landi B, Colin P, Denet C, Mery-Mignard D, Riise M-L, Buyse M, de Gramont A (2001) FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 20: 124a (abstract 494)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ross, P., Cunningham, D. Reply 2: NICE guidelines on drugs for colorectal cancer. Br J Cancer 88, 1154–1155 (2003). https://doi.org/10.1038/sj.bjc.6600853
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6600853